An NMR Study of the Bortezomib Degradation under Clinical Use Conditions

Figure 4

N-(1-(1-hydroxy-3-methylbutylamino)-1-oxo-3- phenylpropan-2-yl) pyrazine-2-carboxamide (BTZ1).